Heart failure
The current guidelines are AHA/ACC/HFSA 2022, and ESC 2021 with its 2023 focused update. Read the ESC 2021 and 2023 documents together: the update changes the HFmrEF, HFpEF, iron and post-discharge recommendations. No new AHA heart failure guideline has been published since 2022; the next one is expected around 2027.
Where they agree
- The same LVEF categories: HFrEF ≤40%, HFmrEF 41–49%, HFpEF ≥50%.
- The same natriuretic peptide cut-offs for suspecting HF in the non-acute setting: NT-proBNP ≥125 pg/mL or BNP ≥35 pg/mL.
- Four drug classes for HFrEF, all Class 1/I: RAS inhibition (ARNI, ACEi or ARB), an evidence-based beta-blocker, an MRA and an SGLT2 inhibitor (dapagliflozin or empagliflozin). Add loop diuretics for congestion.
- SGLT2 inhibitors across the whole EF range.
- CRT for LVEF ≤35%, sinus rhythm, LBBB with QRS ≥150 ms (Class 1/I).
- Ivabradine (2a/IIa) for sinus rhythm with heart rate ≥70 despite a beta-blocker. Digoxin and vericiguat are 2b/IIb.
- Avoid: non-dihydropyridine CCBs, NSAIDs and thiazolidinediones in HFrEF.
Where they differ
| AHA/ACC/HFSA 2022 | ESC 2021 + 2023 update | |
|---|---|---|
| Staging | Stages A–D (at risk, pre-HF, symptomatic, advanced) | NYHA class; no A–D staging |
| Improved EF | Named category HFimpEF (previous ≤40%, now >40%): keep GDMT going | Not a separate category |
| RAS inhibitor of choice in HFrEF | ARNI first (1, A) for NYHA II–III; ACEi only if ARNI isn't feasible | ACEi (I, A); ARNI as a replacement for ACEi (I, B); ARNI started without prior ACEi (de novo) is IIb |
| ICD, non-ischaemic, LVEF ≤35% | 1 (A) | IIa (A) |
| CRT, LBBB with QRS below 150 ms | LBBB 120–149 ms: 2a | LBBB 130–149 ms: IIa; not for QRS <130 |
| HFmrEF: SGLT2i | 2a | I (2023) |
| HFpEF: SGLT2i | 2a | I (2023) |
| HFpEF: MRA / ARB / ARNI | 2b each | Not recommended (focus on comorbidities) |
| IV iron | 2a in HFrEF | I for symptoms and quality of life, IIa to cut hospitalisation (HFrEF and HFmrEF, 2023) |
| Hydralazine + isosorbide dinitrate | 1 in African American patients, NYHA III–IV | IIa in self-identified Black patients |
| After an HF admission | – | Intensive start and fast up-titration of GDMT before discharge and over 6 weeks (I, B; STRONG-HF, 2023) |
Clinical pearls
- "Four pillars" for HFrEF: ARNI/ACEi/ARB + beta-blocker + MRA + SGLT2i. Start them together or in quick succession, at low dose, then up-titrate.
- ARNI–ACEi washout: 36 hours. Never give ARNI or ACEi to a patient with any history of angioedema.
- Evidence-based beta-blockers: bisoprolol, carvedilol and metoprolol succinate (plus nebivolol in ESC).
- MRA: eGFR >30 and K⁺ <5.0 to start (AHA). Stop if K⁺ can't be kept below 5.5.
- Iron deficiency in HF: ferritin <100, or ferritin 100–299 with TSAT <20%.
- CHAMPIT (ESC): the acute causes of HF to look for first. Coronary syndrome, Hypertensive emergency, Arrhythmia, Mechanical cause, Pulmonary embolism, Infection, Tamponade.